Tci Gene Inc.

As of June 30, 2026, Tci Gene Inc. carries a market capitalization of 978.97M, placing it among publicly traded companies globally. Its enterprise value stands at 145.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Tci Gene Inc. has 26.46M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Tci Gene Inc. maintains a current ratio of 8.52, meaning it holds 8.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Tci Gene Inc.'s stock has declined approximately 7.49% over the past 52 weeks. The 50-day moving average sits at 35.44, while the 200-day moving average is 36.04.

As of June 30, 2026, Tci Gene Inc. holds 859.36M in cash and equivalents against 3.88M in total debt, resulting in a net debt position of -136.20M. Total book value stands at 914.51M, with working capital of 849.22M providing operational flexibility.